Immunomodulatory effect of NSAID in geriatric patients with acute infection: effects of piroxicam on chemokine/cytokine secretion patterns and levels of heat shock proteins. A double-blind randomized controlled trial. (ISRCTN58517443)
- 143 Downloads
Inflammation in older persons is associated with frailty, cachexia, and disability. We hypothesized that NSAID treatment in addition to antibiotics in older patients with acute infection might rapidly reduce inflammatory cytokines and might be of therapeutic potential to improve outcomes. A double-blind controlled trial was conducted in geriatric patients admitted for acute infection. Patients were randomized to receive either 10 mg piroxicam or placebo. Patients ≥70 years with CRP levels >10 mg/L of acute infectious origin were eligible. Twenty-five cyto-/chemokines as well as heat shock proteins Hsp27 (HSPB1) and Hsp70 (HSPA1A) were measured the first 4 days and then weekly until discharge, with a maximum of 3 weeks. Thirty Caucasian patients were included (median age 84.5 years, 67% female, median CRP 87.5 mg/L). In the piroxicam group, IL-6 and IP-10/CXCL10 decreased significantly during the study period. Relationships between cytokines were disrupted in the piroxicam group: for 12 out of 20 cytokines the number of correlations between changes in serum levels was significantly lower compared to placebo. Serum Hsp70 levels decreased significantly in the piroxicam group, but not in the placebo group. Without heat challenge, intracellular levels of Hsp70 in monocytes decreased in both groups, whereas HsP27 in monocytes increased with piroxicam with a significant difference compared to placebo at 3 weeks. Piroxicam in this setting cannot be considered merely as an anti-inflammatory drug, but rather as an immunomodulator. Further studies are needed to establish whether these effects can change functional outcomes in geriatric patients.
KeywordsInfection Inflammation Cytokines/chemokines NSAID Piroxicam
The study was in part supported by a grant from the “Wetenschappelijk Fonds Willy Gepts” of the Universitair Ziekenhuis Brussel.
Conflict of interest
I Beyer and T Mets have been investigators in clinical trials sponsored by Pfizer. The present study was an investigator initiated trial receiving no sponsoring and the study medication was produced by the hospital’s pharmacy.
- Bautmans I, Njemini R, Lambert M, Demanet C, Mets T (2005) Circulating acute phase mediators and skeletal muscle performance in hospitalized geriatric patients. j gerontol 60(3):361–367Google Scholar
- Cruse JM, Lewis RE (2010) Cytokines and chemokines. In: Atlas of Immunology, 3rd edn. CRC Press, Boca Raton, FL, pp. 343–381Google Scholar
- Kawaguchi M, Kokubu F, Huang SK, Homma T, Odaka M, Watanabe S, Suzuki S, Ieki K, Matsukura S, Kurokawa M, Adachi M (2007) The IL-17F signaling pathway is involved in the induction of IFN-gamma-inducible protein 10 in bronchial epithelial cells. J allergy clin immunol 119(6):1408–1414PubMedCrossRefGoogle Scholar
- Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, Stiles JK (2011) CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine growth factor reviews. doi: 10.1016/j.cytogfr.2011.06.001
- Stryer L (1995) Biochemistry, 4th edn. WH Freeman Co, San Francisco, pp 918–919Google Scholar